within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD04_GlimepirideAndRosiglitazone;

model GlimepirideAndRosiglitazone
  extends Pharmacolibrary.Drugs.ATC.A.A10BD04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BD04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Glimepiride and rosiglitazone is a fixed-dose combination of an oral sulfonylurea (glimepiride), which stimulates insulin secretion from pancreatic beta cells, and a thiazolidinedione (rosiglitazone), which improves insulin sensitivity in peripheral tissues. The combination is used for the management of type 2 diabetes mellitus in adults. The combination is approved for use in several countries, although rosiglitazone's approval status may vary due to cardiovascular safety concerns.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for healthy adult subjects; individual PK studies generally report on monotherapy, as no published population PK model for the fixed-dose combination was identified.</p><h4>References</h4><ol><li><p>Kirchheiner, J, et al., &amp; Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. <i>Clinical pharmacokinetics</i> 44(12) 1209–1225. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544120-00002&quot;>10.2165/00003088-200544120-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16372821/&quot;>https://pubmed.ncbi.nlm.nih.gov/16372821</a></p></li><li><p>Raptis, SA, &amp; Dimitriadis, GD (2001). Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers. <i>Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association</i> 109 Suppl 2 S265–S287. DOI:<a href=&quot;https://doi.org/10.1055/s-2001-18588&quot;>10.1055/s-2001-18588</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11460577/&quot;>https://pubmed.ncbi.nlm.nih.gov/11460577</a></p></li><li><p>Klatt, S, et al., &amp; König, J (2013). The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 112(4) 244–250. DOI:<a href=&quot;https://doi.org/10.1111/bcpt.12031&quot;>10.1111/bcpt.12031</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23121773/&quot;>https://pubmed.ncbi.nlm.nih.gov/23121773</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end GlimepirideAndRosiglitazone;
